Signalling pathways in the brain: Cellular transduction of mood stabilisation in the treatment of manic-depressive illness

Australian and New Zealand Journal of Psychiatry

Volumn 33, Issue SUPPL., 1999, Pages

  Manji, Husseini K ^a   McNamara, Robert ^b   Chen, Guang ^a   Lenox, Robert H ^b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Lithium; Manic depression; Protein kinase C isozymes; Signalling pathways

Indexed keywords

ISOENZYME; LITHIUM; PROTEIN KINASE C; VALPROIC ACID;

BRAIN; CENTRAL NERVOUS SYSTEM; DRUG EFFECT; GENE EXPRESSION; HUMAN; MANIC DEPRESSIVE PSYCHOSIS; MOOD; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

ADULT; ANTIMANIC AGENTS; BIPOLAR DISORDER; BRAIN; HUMANS; ISOENZYMES; LITHIUM CARBONATE; PROTEIN KINASE C; SIGNAL TRANSDUCTION;

EID: 0033384866     PISSN: 00048674     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1614.1999.033006000.x     Document Type: Review

References (224)

1. Goodwin FK, Jamison KR. Manic-depressive illness. New York: Oxford University Press, 1990.
2. Jamison KR. Suicide and bipolar disorders. Annuals of New York Academy of Science 1986; 487:301-315.
3. Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER. The economic burden of depression in 1990. Journal of Clinical Psychiatry 1993; 54:405-418.
4. Wyatt RJ, Henter I. An economic evaluation of manic-depressive illness. Social Psychiatry and Psychiatric Epidemiology 1995; 30:213-219.
5. Vestergaard P, Aagaard J. Five-year mortality in lithiumtreated manic-depressive patients. Journal of Affective Disorders 1991; 21:33-38.
6. Muller-Oerlinghausen B, Ahrens B. Grof E et al. The effect of long-term lithium treatment on the mortality of patients with manic-depressive and schizoaffective illness. Acta Psychiatrica Scandinavica 1992; 86:218-222.
7. Tondo L, Jamison KR, Baldessarini RJ. Effect of lithium maintenance on suicidal behavior in major mood disorders: Annals to the New York Academy of Sciences 1997; 836:339-351.
8. Schou M. Clinical aspects of lithium in psychiatry. In: Birch NJ, ed. Lithium and the Cell. London: Academic Press, 1991:1-6.
9. Reifman A, Wyatt RJ. Lithium: A brake in the rising cost of mental illness. Archives of General Psychiatry 1980; 37:385-388.
10. Manji HK, Potter WZ, Lenox RH. Signal transduction pathways: molecular targets for lithium's actions. Archives of General Psychiatry 1995; 52:531-543.
11. Lenox RH, Manji HK, Lithium. In Nemeroff CB. Schatzberg AF (eds). American Psychiatric Press Textbook of Psychopharmacology, 2nd ed. American Psychiatric Press Inc, Washington DC. 1998:379-430.
12. Jope RS. A bimodal model of the mechanism of action of lithium. Molecular Psychiatry 1999; 4:21-25.
13. Kramlinger KG, Post RM. The addition of lithium to carbamazepine: antidepressant eficancy in treatment-resistent mania. Archives of General Psychiatry 1989; 46:794-800.
14. Chou JC, Recent advances in treatment of acute mania. Journal of Clinical Psychopharmacology 1991; 11:3-21.
15. Lenox RH. Role of receptor coupling to phosphoinositide metabolism in therapeutic action of lithium. Advances in Experimental Medicine and Biology 1987; 221:515-530.
16. Lenox RH, Watson DG. Lithium and the Brain: A psychopharmacological strategy to a molecular basis for manic depressive illness. Clinical Chemistry 1994; 40:309-314.
17. Ikonomov O, Manji HK. Molecular mechanism of action of lithium: beyond signal transduction. American Journal of Psychiatry 1999; 156:1506-1514.
18. Small JG, Klapper MH, Milstein V et al. Carbamazepine compared with lithium in the treatment of mania. Archives of General Psychiatry 1991; 48:915-921.
19. Post RM, Leverich GS, Altshuler L et al. Lithium-discontinuation induced refractoriness: preliminary observations. American Journal of Psychiatry 1992; 149:1727-1729.
20. McElroy SL, Keck PE, Stanton SP et al. A randomised comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. Journal of Clinical Psychiatry 1996; 57:142-146.
21. Bowden CL, Brugger AM, Swann AC et al. Efficacy of divalproex vs. lithium and placebo in the treatment of mania. JAMA 1994; 271:918-924.
22. Bowden CL. Lithium comparison to valproate and carbamazepine 1996. XXth CINP Congress.
23. Fyre MA, Altshuler LL, Szuba MP et al. The relationship between antimanic agent for treatment of classic or dysphoric mania and length of hospital stay. Journal of Clinical Psychiatry 1996; 57:17-21.
24. Hsiao JK, Argen H, Bartko JJ, Rudorfer MV, Linnoila M, Potter WZ. Monoamine neurotransmitter interactions and the prediction of antidepressant response. Archives of General Psychiatry 1987; 44:1078-1083.
25. Hsiao JK, Colison J. Bartko JJ et al. Monoamine neuro-transmitter interactions in drug-free and neuroleptic-treated schizophrenics. Archives of General Psychiatry 1993; 50:606-614.
26. Manji HK. G proteins: implications for psychiatry. American Journal of Psychiatry 1992; 149:746-460.
27. Meltzer HY. The importance of serotonin-dopamine interactions in the action of clozapine. British Journal of Psychiatry 1992; 17:22-29.
28. Mandell AJ, Knapp S, Ehlers C et al. The stability of constrained randomness: Lithium prophylaxis at several neurobiological levels. In: Post RM, Ballenger JC, eds. Neurobiology of Mood Disorders. Baltimore: Williams & Wilkins, 1984:744-776.
29. Depue RA, Karuss SP, Spoont MR. A two-dimensional threshold model of seasonal bipolar affective disorder. In: Magnusson D, ed. Psychopathology: An Interactional Perspective. Ohman A. Orlando: Academic Press, 1987:95-123.
30. Wang JF, Young LT, Li PP, Warsh JJ. Signal Transduction abnormalities in Bipolar Disorder. In: Young LT and Joffe RT, eds. Bipolar Disorder: biological models and their clinical applications. New York: Marcel Dekker, 1997:41-79.
31. Ross EM. Signal sorting and amplification through G protein-coupled receptors. Neuron 1989; 3:141-152.
32. Taylor CW. The role of G proteins in transmembrane signalling. Biochemical Journal 1990; 272:1-13.
33. Bourne HR, Nicoll R. Molecular machines integrate coincident synaptic signals. Cell 1993; 72:65-75.
34. Suppes T, Baldessarini RJ, Faedda GL et al. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Archives of General Psychiatry 1991; 48:1082-1088.
35. Faedda GL, Tondo L, Baldessarini RJ et al. Outcome after rapid vs gradual discontinuation of lithium treatment in bipolar mood disorders. Archives of General Psychiatry 1993;50: 448-455.
36. Goodnick PJ, Gershon ES. Lithium. In: Lajtha A, ed. Handbook of Neurochemistry. New York, NY: Plenum Press, 1985:103-149.
37. Bunney WE Jr, Garland-Bunney B. Mechanisms of action of lithium in affective illness: Basic and clinical implications. In: Meltzer HY, ed. Psychopharmacology: The Third Generation of Progress. Raven Press: New York, 1987: 553-565.
38. Risby ED, Hsiao JK, Manji HK et al. The mechanisms of action of lithium. II. Effects on adenylate cyclase activity and beta-adrenergic receptor binding in normal subjects. Archives of General Psychiatry 1991; 48:513-524.
39. Berridge MJ, Downes CP, Hanley MR. Lithium amplifies agonist-dependent phosphatidylinositol responses in brain and salivary glands. Biochemistry Journal 1982; 206:587-595.
40. Baraban JM, Worley PF, Snyder SH. Second messenger systems and psychoactive drug focus on the phosphoinositide system and lithium. American Journal of Psychiatry 1989; 146:1251-1260.
41. Allison JH, Stewart MA. Reduced brain inositol in lithium treated rats. Nature 1971; 233:267-268.
42. Hallcher LM, Sherman WR. The effects of lithium ion and other agents on the activity of myoinositol-1-phosphatase from bovine brain. Journal of Biological Chemistry 1980; 255:0896-10901.
43. Sherman WR. Lithium and the phosphoinositide signalling system. In: Birch NJ, ed. Lithium and the cell. London: Academic Press 1991:121-157.
44. Nahorski SR, Ragan CI, Challiss RAJ. Lithium and the phosphoinositide cycle: an example of uncompetitive inhibition and its pharmacological consequences. Tips 1991; 12:297-303.
45. Nahorski SR, Jenkinson S, Challiss RA. Disruption of phosphoinositide signalling by lithium. Biochemistry Society Transactions 1992; 20:430-434.
46. Berridge MJ, Downes CP, Hanley MR. Neural and developmental actions of lithium: a unifying hypothesis. Cell 1989; 59:411-419.
47. Rana RS, Hokin LE. Role of Phosphoinositides in transmembrane signalling. Physiology Revue 1990; 70:115-164.
48. Chuang DM. Neurotransmitter receptors and phophoinositide turnover. Annual Revue of Pharmacology and Toxicology 1989; 29:71-110.
49. Fisher SK, Heacock AM, Agranoff BW. Inositol lipids and signal transduction in the nervous system: an update. Journal of Neurochemistry 1992; 58:18-38.
50. Casebolt TL, Jope RS. Chronic lithium reduces norepinephrine-stimulated inositol phospholipid hydrolysis in rat cortex. European Journal of Pharmacology 1987; 140:245-246.
51. Casebolt TL, Jope RS. Long-term lithium treatment selectively reduces receptor-coupled inositol phospholipid hydrolysis in rat brain. Biological Psychiatry 1989; 25:329-340.
52. Whitworth P, Kendall DA. Lithium selectively inhibits muscarinic receptor-stimulated inositol tetrakisphosphate accumulation in mouse cerebral cortex slices. Journal of Neurochemistry 1988; 51:258-265.
53. Godfrey PP, McClue SJ, White AM, Wood AJ, Grahame-Smith DG. Potentiation by lithium of CMP-phosphatidate formation in carbachol-stimulated rat cerebral-cortical slices and its reversal by myo-inositol. Biochemistry Journal 1989; 258:621-624.
54. l receptor-mediated cyclic AMP formation by carbachol in rat brain slices. Journal of Neurochemistry 1989; 53:536-541.
55. Kennedy ED, Challiss RJ, Nahorski SR. Lithium reduces the accumulation of inositol polyphosphate second messengers following cholinergic stimulation of cerebral cortex slices. Journal of Neurochemistry 1989; 53:1652-1655.
56. Ellis J, Lenox RH. Chronic lithium treatment prevents atropine-induced supersensitivity of the muscarinic phosphoinositide response in rat hippocampus. Biological Psychiatry 1990; 28:609-619.
57. Song L, Jope R. Chronic lithium treatment impairs phosphatidylinositol hydroysis in membranes from rat brain regions. Journal of Neurochemistry 1992; 58:2200-2206.
58. Sherman WR, Munsell LY, Gish BG et al. Effects of systemically administered lithium on phosphoinositide metabolism in rat brain, kidney, and testis. Journal of Neurochemistry 1985; 44:798-807.
59. Nishizuka Y. Intracellular signalling by hydrolysis of phospholipids and activation of protein kinase C. Science 1992; 258:607-614.
60. Manji HK, Lenox RH. Long-term action of lithium: A role for transcriptional and posttranscriptional factors regulated by protein kinase C. Synapse 1994; 16:11-28.
61. 3 pituitary cells. Molecular Pharmacology 1992; 4:671-678.
62. Kennedy ED, Challiss RAJ, Ragan CI et al. Reduced inositol polyphosphate accumulation and inositol supply induced by lithium in stimulated cerebral cortex slices. Biochemistry Journal 1990; 267:781-786.
63. Kendall DA, Nahorski SR. Acute and chronic lithium treatments influence agonist and depolarization-stimulated inositol phospholipid hydrolysis in rat cerebral cortex. Journal of Pharmacology Experiments and Therapeutics 1987; 241:1023-1027.
64. Maslanski JA, Leshko L, Busa WB. Lithium-sensitive production of inositol phosphates during amphibian embryonic mesoderm induction. Science 1992; 256:243-245.
65. Tricklebank MD, Singh L, Jackson A, Oles RJ. Evidence that a proconvulsant action of lithium is mediated by inhibition of myo-inositol phosphatase in mouse brain. Brain Research 1991; 558:145-148.
66. Kofman O, Belmaker RH. Biochemical, behavioral and clinical studies of the role of inositol in lithium treatment and depression. Biological Psychiatry 1993; 34:839-852.
67. Moore GJ, Bebchuk JM, Parrish JK et al. Temporal dissociation between lithium-induced CNS myo-inosilol changes and clinical response in manic-depressive illness. American Journal of Psychiatry 1999; (in press).
68. Manji HK, Bebchuk JM, Moore GJ, Glitz D, Hasanat K, Chen G. Modulation of CNS signal transduction pathways and gene expression by mood stabilizing agents: therapeutic implications. Journal of Clinical Psychiatry 1999; 60:27-39.
69. Moore GJ. Bebchuk JM, Parrish JK et al. Lithium induced neurochemical changes in bipolar disorder: in vivo investigation of the inositol depletion hypothesis. Proceedings of the International Society of Magnetic Resonance in Medicine, Sydney, 1998 (abstract 504).
70. Manji HK, Lenox RH. Protein kinase C signalling in the brain: molecular transduction of mood stabilization in the treatment of bipolar disorder. 1999 Ziskind-Somerfeld Award Paper. Biological Psychiatry 1999: in press.
71. Manji HK, Chen G, Hsiao JK, Masana MI, Potter WZ. Regulation of signal transduction pathways by mood stabilizing agents: implications for the pathophysiology and treatment of bipolar affective disorder. In: Manji HK, Bowden CL and Belmaker RH, eds. Bipolar medications: mechanisms of action. American Psychiatric Press Inc., Washington DC. 1999 (in press).
72. Forn J, Valdecasas FG. Effects of lithium on brain adenylyl cyclase activity. Biochemistry pharmacology 1971; 20:2773-2779.
73. Dousa T, Hechter O. Lithium and brain adenyl cyclase. Lancet 1970; 1:834-835.
74. Dousa T, Hechter O. The effect of NaCl and LiCl on vasopressin-sensitive adenyl cyclase. Life Science 1970b; 9:765-770.
75. Singer I, Rotenberg D, Puschett JB. Lithium-induced nephrogenic diabetes insipidus: in vivo and in vitro studies. Journal of Clinical Investigation 1972; 51:1081-1091.
76. Singer I, Rotenberg D. Mechanisms of lithium action. New England Journal of Medicine 1973; 289:254-260.
77. Gelfand EW, Dosch HM, Hastings B, Shore A. Lithium: a modulator of cyclic AMP-dependent events in lymphocytes. Science. 1979; 203:365-367.
78. Ebstein RP, Hermoni M, Belmaker RH. The effect of lithium on noradrenaline-induced cyclic AMP accumulation in rat brain: inhibition after chronic treatment and absence of supersensitivity. Journal of Pharmacology Expeximents and Therapeutics 1980; 213:161-167.
79. Belmaker RH. Receptors, adenylate cyclase, depression, and lithium. Biological Psychiatry 1981; 16:333-350.
80. Ebstein R, Oppenheim G, Ebstein BS et al. The cyclic AMP second messenger system in man: the effects of heredity, hormones, drugs, aluminum, age and disease on signal amplification. Biological Psychiatry 1986; 10:323-353.
81. Ebstein RP, Moscovich D, Zeevi S, Amiri Z, Lerer B. Effect of lithium in vitro and after chronic treatment on human platelet adenylate cyclase activity: prosreceptor modification or second messenger signal amplification. Psychiatry Research 1987; 21:221-228.
82. Geisler A, Klysner R, Andersen PH. Influence of lithium in vitro and in vivo on the catecholamine-sensitive cerebral adenylate cyclase systems. Acta Pharmacological Toxicological (Copenhagen) 1985: 56:80-97.
83. Newman ME, Belmaker RH. Effects of lithium in vitro and ex vivo on components of the adenylate cyclase system in membranes from the cerebral cortex of the rat. Neuropharmacology 1987; 26:211-217.
84. Mork A, Geisler A. Effects of GTP on hormone-stimulated adenylate cyclase with activity in cerebral cortex, striatum, and hippocampus from rats treated chronically with lithium. Biological Psychiatry 1989a; 26:279-288.
85. Mork A, Geisler A. The effects of lithium in vitro and ex vivo on adenylate cyclase in brain are exerted by distinct mechanisms. Neumpharmacology 1989b; 28:307-311.
86. Mork A, Geisler A. Effects of lithium ex vivo on the GTP-mediated inhibition of calcium-stimulated adenylate cyclase activity in rat brain. European Journal of Pharmacology 1989; 168:347-354.
87. Mork A, Geisler A, Hollund P. Effects of lithium on second messenger systems in the brain. Pharmacological Toxicology 1992; 71:4-71.
88. Newman M, Klein E et al. Lithium at therapeutic concentrations inhibits human brain noradrenaline sensitive cyclic AMP accumulation. Brain Research 1983; 278:380-381.
89. Friedman E, Dallob A, Levine G. The effect of long-term lithium treatment on reserpine-induced supersensitivity in dopaminergic and serotonergic transmission. Life Sciences 1979; 25:1263-1266.
90. Belmaker RH, Kon M, Epstein RP, Dasberg H. Patrial inhibition by lithium of the epinephrine-stimulated rise in plasma cyclic GMP in humans. Biological Psychiatry 1980; 15:3-8.
91. Ebstein RP, Lerer B, Shlaufman M et al. The effect of repeated electroconvulsive shock treatment and chronic lithium feeding on the release of norepinephrine from rat cortical vesicular preparations. Molecular Neurobiology 1983; 3:191-201.
92. Newman ME, Lerer B, Lichtenberg P, Shapira B. Platelet adenylate cyclase activity in depression and after clomipramine and lithium treatment. Psychopharmacology 1992; 109:231-234.
93. Lonati-Galligani M, Emrich HM, Raptis C, Pirke KM. Effects of in vivo lithium treatment on (-) isoproterenol-stimulated cAMP accumulation in lymphocytes of healthy subjects and patients with affective psychoses. Pharmacopsychiatry 1989; 22:241-245.
94. Dousa TP. Interaction of lithium with vasopressin-sensitive cyclic AMP system of human renal medulla. Endocrinology 1974; 95:1359-1366.
95. Goldberg H. Clayman P. Skorecki K. Mechanism of Li inhibition on vasopressin-sensitive adenylate cyclase in cultured renal epithelial cells. American Journal of Physiology 1988; 24: F995-F1002.
96. Tseng FY, Pasquali D, Field JB. Effects of lithium on stimulated metabolic parameters in dog thyroid slices. Acta Endocrinologica (Copenhagen) 1989; 121: 615-620.
97. Urabe M, Hershman JM, Pang XP, Murakami S, Sugawara M. Effect of lithium on function and growth of thyroid cells in vitro. Endocrinology 1991; 129:807-814.
98. Andersen PH. Geisler A. Lithium inhibition of forskolin-stimulated adenylate cyclase. Neuropsychobiology 1984: 12:1-3.
99. Mork A, Geisler A. Mode of action of lithium on the catalytic unit of adenylate cyclase from rat brain. Pharmacological Toxicology 1987; 60:241-248.
100. Masana Ml, Bitran JA, Hsiao JK, Mefford IN, Potter WZ. Lithium effects on noradrenergic linked adenylate cyclase activity in intact rat brain: an in vivo microdialysis study. Brain Research 1991; 538:333-336.
101. Avissar S, Schreiber G, Danon A et al. Lithium inhibits adrenergic and cholinergic increases in GTP binding in rat cortex. Nature 1988; 331:440-442.
102. Ellis J, Lenox RH. Receptor coupling to G proteins, interactions not affected by lithium. Lithium 1991; 2:141-147.
103. Newman ME, Shapira B, Lerer B. Effects of lithium and desimipramine on second messenger responses in rat hippocampus: relation to G protein effects. Neuropharmacology 1991; 30: 297-1301.
104. Manji HK, Hsiao JK, Risby ED. The mechanisms of action of lithium. Archives of General Psychiatry. 1991; 48:505-512.
105. Masana MI, Bitran JA, Hsiao JK et al. In vivo evidence that lithium inactivates Gi modulation of adenylate cyclase in brain. Journal of Neurochemistry 1992; 59:200-205.
106. Wang HY, Friedman E. Effects of lithium on receptor-mediated activation of G proteins in rat brain cortical membranes. Neuropharmacology 1999; 38:403-414.
107. Ui M. Pertussis toxin as a valuable probe for G protein involvement in signal transaction. In: Moss J, Vaughn M, eds. ADP-ribosylation toxin and G proteins. Washington, DC: American Society for Microbiology, 1990:45-79.
108. Turkka J, Bitran JA, Manji HK, Linnoila M, Potter WZ. Effects of chronic lithium on agonist and antagonist binding to b adrenergic receptors of rat brain. Lithium 1992; 3:43-47.
109. Li PP, Tam YK, Young LT et al. Lithium decreases Gs, Gi-1 and Gi-2 alpha-subunit mRNA levels in rat cortex. European Journal of Pharmacology 1991; 206:165-166.
110. Colin SF, Chang HC, Mollner S et al. Chronic lithium regulates the expression of adenylate cyclase and Gi-protein alpha subunit in rat cerebral cortex. Procedures of the National Academy of Sciences of the United State of America 1991; 88:10 634-10 637.
111. Hsiao JK, Manji HK, Chen GA et al. Lithium administration modulates platelet Gi in humans. Life Science 1992; 50:227-233.
112. Garcia-Sevilla JA, Guimon J, Garcia-Vallejo P et al. Biochemical and functional evidence of supersensitive platelet alpha-2-adrenoceptors in major affective disorder. Effect of long-term lithium carbonate treatment. Archives of General Psychiatry 1986; 43:51-57.
113. Smith CB, Hollingsworth PJ, Garcia-Sevilla JA, Zis AP. Platelet alpha 2 adrenoreceptors are decreased in number after antidepressant therapy. Progress in Neuro-psychopharmacology and Biological Psychiatry 1983; 7:241-247.
114. 2 adrenoceptors and the inhibitory G protein (Gi) in human platelets. FEBS Letters. 1989; 257:427-430.
115. Halenda SP, Volpi M, Zavoico GB, Shaafi RI, Feinstein MB. Effects of thrombin, phorbol myristate acetate, and prostaglandin D2 on 40-41 kDa protein that is ADP ribosylated by pertussis toxin in platelets. Febs Letters 1986; 204:341-346.
116. Houslay MD. 'Crosstalka': pivotal role for protein pathways. Europen Journal of Biochemistry 1991; 195:9-27.
117. Sagi-Eisenberg R. GTP-binding proteins as possible targets for protein kinase C action. Trends in Biochemical Sciences 1989; 14:355-357.
118. Huganir RL, Greengard P. Regulation of neurotransmitter receptor desensitization by protein phosphorylation. Neuron 1990; 5:555-567.
119. Katada T. Gillman AG, Watanabe Y, Bauer S, Jakobs KH. Protein C phosphorylates the inhibitory guanine-nucleotide-binding regulatory component and apparently suppresses its function in hormonal inhibition of adenylate cyclase. European Journal of Biochemistry 1985; 151:431-437.
120. Olianas MC, Onali P. Phorbol esters increase GTP-dependent adenylate cyclase activity in rat brain striatal membranes. Journal of Neurochemistry 1986; 7:890-897.
121. Thiele EA, Eipper BA. Effect of secretogogues on components of the secretory system in AtT-20 cells. Endocrinology 1990; 126:809-817.
122. Manji HK, Bersudsky Y, Chen G. Belmaker RH, Potter WZ. Modulation of PKC isozymes and substrates by lithium: the role of myo-inositol. Neuropsychopharmacology 1996; 15:370-382.
123. Stabel S, Parker PJ. Protein kinase C. Pharmacology Therapeutics 1991; 51:71-95.
124. Huang KP. The mechanism of protein kinase C activation. Trends in Neuroscience 1989; 12:425-432.
125. Anderson SMP, Godfrey PP, Grahame-Smith DG. The effects of phorbol esters and lithium on 5-HT release in rat hippocampal slices. British Journal of Pharmacology 1988; 93:96P.
126. Bitran JA, Potter WZ, Manji HK et al. Chronic Li+ attenuates agonist- and phorbol ester-mediated Na+/Ha+ antiporter activity in HL-60 cells. European Journal of Pharmacology 1990; 188:193-202.
127. Evans MS. Zorumski CF. Clifford DB. Lithium enhances neuronal muscarinic excitation by presynaptic facilitation. Neuroscience 1990; 38:457-468.
128. Lenox RH, Watson DGJP, Ellis J. Chronic lithium administration alters a prominent PKC substrate in rat hippocampus. Brain Research 1992; 570:333-340.
129. Manji HK, Etcheberrigaray R, Chcn G, Olds JL. Lithium decreases membrane-associated Protein kinase C in hippocampus: selectivity for the a isozyme. Journal of Neurochemistry 1993; 61:2303-2310.
130. Reisine T, Zatz M. Interactions between lithium, calcium, diacylglycerides and phorbol esters in the regulation of ACTH release from AtT-20 cells. Journal of Neurochemistry 1987; 49:884-889.
131. Sharp T, Bramwell SR, Lambert P et al. Effect of short- and long-term administration of lithium on the release of endogenous 5-HT in the hippocampus of the rat in vivo and in vitro. Neuropharmacology 1991; 30:977-984.
132. Wang HY, Friedman E. Lithium inhibition of protein kinase C activation-induced serotonin release. Psychopharmacology (Berlin) 1989; 99:213-218.
133. Zatz M, Reisine TD. Lithium induces corticotropin secretion and de-sensitisation in cultured anterior pituitary cells. Proceedings of the National Academy of Sciences of the United States of America 1985; 82:1286-1290.
134. Young S, Parker PJ, Ullrich A, Stabel S. Down-regulation of protein kinase C is due to an increased rate of degradation. Biochemistry Journal 1987; 24:775-779.
135. Kishimoto A, Mikawa K, Hashimoto K et al. Limited proteolysis of protein kinase C subspecies by calcium-dependent neutral protease (calpain). Journal of Biological Chemistry 1989; 264:4088-4092.
136. Isakov N, McMahon P, Altman A. Selective post-transcriptional down-regulation of protein kinase C isoenzymes in Leukemic T cells chronically treated with phorbol ester. Journal of Biological Chemistry 1990; 265:2091-2097.
137. Borner C, Guadagno SN, Fabbro D, Weinstein I. Expression of four protein kinase C isoforms in rat fibroblasts. Distinct subcellular distribution and regulation by calcium and phorbol esters. Journal of Biological Chemistry 1992; 267: 12892-12899.
138. Goodnight J, Mischak H, Kolch W, Mushinski JF. Immunocytochemical localisation of eight protein kinase C isozymes overexpressed in NIH 3T3 fibroblasts. Journal of Biological Chemistry 1995; 270:9991-10001.
139. Leli U, Hauser G. Lithium modifies diacylglycerol levels and protein kinase C in neuroblastoma cells. Abstracts of the 8th International Conference on Second Messengers and Phosphoproteins, 1992, Z187F.
140. Jope RS, Song L, Li PP et al. The phosphoinositide signal transduction system is impaired in bipolar affective disorder brain. Journal of Neurochemistry 1996; 66:2402-2409.
141. Brami BA, Leli U, Hauser G. Influence of lithium on second messenger accumulation in NG108-15 cells. Biochemistry Biophysiology Research Communication 1991a; 174:606-612.
142. Brami BA, Leli U, Hauser G. Origin of the diacylglycerol produced in excess of inositol phosphates by lithium in NG108-15 cells. Journal of Neurochemistry 1991b; 57:S9.
143. Casebolt TL, Jope RS. Effects of chronic lithium treatment on protein kinase C and cyclic AMP-dependent protein phosphorylation. Biological Psychiatry 1991; 29:233-243.
144. Jensen JB, Mork A. Altered protein phosphorylation in the rat brain following chronic lithium and carbamazepine treatments. European Neuropsychopharmacology 1997; 7:173-9.
145. Aderem A. The MARCKS brothers: a family of protein kinase C substrates. Cell 1992; 71:713-716.
146. Blackshear PJ. The MARCKS family of cellular protein kinase C substrates. Journal of Biological Chemistry 1993; 268:1501-1504.
147. Swierezynski SL, Blackshear PJ. Membrane association of the myristoylated alanine-rich C kinase substrate (MARCKS) protein. Mutational analysis provides evidence for complex interactions. Journal of Biological Chemistry 1995; 270:13436-13445.
148. Ouimet CC, Wang JKT, Walaas SI et al. Localization of the MARCKS 87 (kDa) protein, a major specific substrate for the protein kinase C, in rat brain. Journal of Neuroscience 1990; 10:683-1698.
149. Seykora JT, Ravetch JV, Aderem A. Cloning and molecular characterization of the murine macrophage '68-kDa' protein kinace C substrate and its regulation by bacterial lipopolysaccharide. Proceedings of the National Academy of Sciences of the United States of America 1991; 88:2505-2509.
150. McNamara RK, Lenox RH. Comparative distribution of myristoylated alanine-rich C kinase substrate (MARCKS) and FI/GAP-43 gene expression in the adult rat brain. Journal of Comparative Neurology 1997; 379:48-71.
151. McNamara RK, Hyde TM, Kleinman JE, Lenox RH. Expression of the myristoylated alanine-rich C kinase substrate (MARCKS) and MARCKS-related protein (MRP) in the hippocampus and prefrontal cortex of suicide victims. Journal of Clinical Psychiatry 1999; 60:21-26.
152. McNamara RK, Lenox RH. Distribution of protein kinase C substrates MARCKS and MRP in the postnatal developing rat brain. Journal of Comparative Neurology 1998a; 397:337-356.
153. Stumpo DJ, Bock CB, Tuttle JS, Blackshear PJ. MARCKS deficiency in mice leads to abnormal brain development and perinatal death. Proceedings from the National Academy of Sciences of the United States of America 1995; 92:944-948.
154. Schnizer RA, McNammara RK, Streit WJ, Lenox RH. Differential expression of MARCKS, MRP & GAP-43 mRNA in the facial nucleus during neuronal regeneration and degeneration. Society for Neuroscience Abstracts 1997; 23:612.
155. McNamara RK, Stumpo DJ, Morel LM et al. Effects of reduced myristoylated alanine rich C-kinase substrate expression on spatial learning in mutant mice: transgenic rescue and interaction with gene background. Proceedings of the National Academy of Sciences of the United States of America 1998b; 95:14517-14522.
156. Watson DG, Lenox RH. Chronic lithium-induced down-regulation of MARCKS in immortalised hippocampal cells: potentiation by muscarinic receptor activation. Journal of Neurochemistry 1996; 67:767-777.
157. Batty IH, Downes CP. The inhibition of phosphoinositide synthesis and muscarinic-receptor-mediated phospholipase C activity by Li+ as secondary, selective consequences of inositol depletion in 132lNl cells. Biochemistry Journal 1994; 297:529-537.
158. Gray DW, Challiss RA. Nahorski SR. Differential effects of lithium on muscarinic cholinoceptor-stimulated CMP-phosphatidate accumulation in cerebellar granule cells, CHO-M3 cells, and SH-SY5Y neuroblastoma cells. Journal of Neurochemistry 1994; 63:1354-1360.
159. Glanville NT, Byers DM, Cook HW, Spence MW, Palmer FB. Differences in the metabolism of inositol and phosphoinositides by cultured cells of neuronal and glial origin. Biochemica Et Biophysica Acta 1989; 1004:169-179.
160. Gani D, Downes CP, Batty I, Bramham J. Lithium and myoinositol homeostasis. Biochemica Et Biophysica Acta 1993; 1177:253-269.
161. Bevilaqua JA, Downes CP, Lowenstein PR, Visualization of agonist-stimulated inositol phospholipid turnover in individual neurons of the rat cerebral cortex and hippocampus. Neuroscience 1994; 60:945-958.
162. Sillence DJ, Downes CP. Lithium treatment of affective disorders: effects of lithium on the inositol phospholipid and cyclic AMP signalling pathways. Biochemica Et Biophysica Acta 1992; 1138:46-52.
163. Stubbs EB, Agranoff BW. Lithium enhances muscarinic receptor-stimulated CDP-diacylglycerol formation in inositol-depleted SK-N-SH neuroblastoma cells. Journal of Neurochemistry 1993; 60:1292-1299.
164. Drummond AH, Raeburn CA. The interaction of lithium with thyrotropin releasing hormone-stimulated lipid metabolism in GH3 pituitary tumor cells. Biochemistry Journal 1984; 224:129-136.
165. Downes CP, Stone MA. Lithium-induced reduction in intracellular inositol supply in cholinergically stimulated parotid gland. Biochemistry Journal 1986; 234:199-204.
166. Brami BA, Leli U, Hauser G. Elevated phosphatidyl-CMP is not the source of diacylglycerol accumulation induced by lithium in NG108-15 cells. Journal of Neurochemistry 1993; 60:1137-1142.
167. Chen G, Manji HK, Hawver DB et al. Chronic sodium valproate selectively decreases protein kinase C α and ε in vitro. Journal of Neurochemistry 1994; 63:2361-2364.
168. Chen G, Yuan PX, Jiang Y, Huang LD, Manji HK. Lithium increases tyrosine hydroxylase levels both in vivo and in vitro. Journal of Neurochemistry 1998; 69:1768-1771.
169. Watson DG, Watterson JM, Lenox RH. Sodium valproate down-regulates the myristoylated alanine-rich C kinase substrate (MARCKS) in immortalized hippocampal cells: a property of protein kinase C-mediated mood stabilisers. Journal of Pharmacology and Experimental Therapeutics 1998; 285:307-316.
170. Keck PE Jr, McElroy SL, Nemeroff CB. Anticonvulsants in the treatment of bipolar disorder. Journal of Neuropsychiatry and Clinical Neuroscience 1992; 4:395-405.
171. Chen G, Hawver D, Wright C, Potter WZ, Manji HK. Attenuation of adenylyl cyclases by carbamazepine in vitro. Journal of Neurochemistry 1996; 67:2079-2086.
172. Conn PJ, Sweatt JD. Protein Kinase C in the Nervous System. In: JF Kuo, ed. Protein Kinase C. Oxford University Press: New York, 1994:199-235.
173. Jordan VC. A current view of tamoxifen for the treatment of breast cancer. British Journal of Pharmacology 1994; 110:507-517.
174. Catherino WH, Jordan VC. A risk-benefit assessment of tamoxifen therapy. Drug Safety 1993; 8:381-397.
175. Couldwell WT, Weiss MH, DeGiorgio CM et al. Clinical and radiographic response in patients with recurrent malignant gliomas treated with high-dose tamoxifen. Neurosurgery 1993; 32:485-489.
176. Bebchuk JM, Arfken CL, Dolan-Manji S, Murphy J, Manji HK. A preliminary investigation of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania. Archives of General Psychiatry 1999 (in press).
177. Freidman E, Hoau YW, Levinson D, Connell TA, Singh H. Altered platelet protein kinase C activity in bipolar affective disorder, manic episode. Biological Psychiatry 1993; 33:520-525.
178. Wang HY, Friedman E. Enhanced protein kinase C activity and translocation in bipolar affective disorder brains. Biological Psychiatry 1996; 40:568-575.
179. Wang HY, Markowitz P, Levinson D, Undie AS, Friedman E. Increased membrane-associated protein kinase C activity and translocation in blood platelets from bipolar affective disorder patients. Journal of Psychiatric Research 1999; 33:171-179.
180. Hyman SE, Nestler EJ. Initiation and adaptation: a paradigm for understanding psychotropic drug action. American Journal of Psychiatry 1996; 153:151-162.
181. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Archives of General Psychiatry 1997; 54:597-606.
182. Karin M, Smeal T. Control of transcription factors by signal transduction pathways: the beginning of the end. TIBS 1992; 17:418-422.
183. Hughes P, Dragunow M. Pharmacological Reviews 1995; 47:133-178.
184. Asghari V, Wang JF, Reiach JS, Young LT. Differential effects of mood stabilisers on Fos/Jun proteins and AP-1 DNA binding activity in human neuroblastoma SH-SY5Y cells. Brain Research. Molecular Brain Research 1998; 58:95-102.
185. Ozaki N, Chuang DM. Lithium increases transcription factor binding to AP-1 and cyclic AMP-responsive element in cultured neurons and rat brain Journal of Neurochemistry 1997; 69:2336-2344.
186. Unlap MT, Jope RS. Lithium attenuates nerve growth factor-induced activation of AP-1 DNA binding activity in PC12 cells. Neuropsychopharmacology 1997; 17:12-17.
187. Williams MB, Jope RS. Circadian variation in rat brain AP-1 DNA binding activity after cholinergic stimulation: modulation by lithium. Psychopharmacology (Bert) 1995; 122:363-368.
188. Yuan PX, Chen G, Manji HK. Concordant regulation of gene expression by lithium and valproic acid in vitro. Society for Neuroscience Abstracts 1996; 22:95.14.
189. Yuan PX, Chen G, Manji HK. Lithium stimulates gene expression through the AP-1 transcription factor pathway. Molecular Brain Research 1998; 58:225-230.
190. Chen G, Yuan PX, Jiang Y, Huang LD, Manji HK. Valproate robustly enhances AP-1 mediated gene expression. Molecular Brain Research 1999c; 64:52-58.
191. Chen DF, Schneider GE, Martinou JC, Tonegawa S. Bc1-2 promotes regeneration of severed axons in mammalian CNS. Nature 1997; 385:434-439.
192. Chen G, Yuan P, Hawver D, Potter WZ, Manji HK. Increase in AP-1 Transcription Factor DNA binding activity by valproic acid. Neuropsychopharmacology 1997; 16:238-245.
193. Kumer SC, Vrana KE. Intricate regulation of tyrosine hydroxylase activity and gene expression. Journal of Neurochemistry 1996; 67:443-461.
194. Drevets WC, Videen TO, Price JL, Preskorn SH, Carmichael ST, Raichle ME. A functional anatomical study of unipolar depression. Journal of Neuroscience 1992; 12:3628-3641.
195. Drevets WC, Price JL, Simpson JR Jr et al. Subgenual prefrontal cortex abnormalities in mood disorders. Nature 1997; 38:824-827.
196. Scares JC, Dippold CS, Mallinger AG. Platelet membrane phosphatidylinositol-4.5-bisphosphate alterations in bipolar disorder - evidence from a single case study. Psychiatry Research 1997; 69:197-202.
197. Ketter TA, George MS, Kimbrell TA, Willis MW, Benson BE, Post RM. Neuroanatomical models and brain imaging studies. In: Joffe RT and Young LT, eds. Bipolar disorder: Biological models and their clinical application. New York, NY: Marcel Dekker Inc., 1997.
198. Boyle WJ, Smeal T, Defize LH et al. Activation of protein kinase C decreases phosphorylation of c-Jun at sites that negatively regulate its DNA-binding activity. Cell 1991; 64:573-584.
199. Lin A, Smeal T, Binetruy B, Deng T, Chambard JC, Karin M. Control of AP-1 activity by signal transduction cascades. Advances in Second Messenger and Phosphoprotein Research 1993; 28:255-260.
200. Hedgepeth CM, Conrad LJ, Zhang J, Huang HC, Lee VMY, Klein PS. Developmental Biology 1997; 185:82-91.
201. Klein PS, Melton DA. Proceedings of the National Academy of Science of the United States of America 1996; 93:8455-8459.
202. Stambolic V, Ruel Laurent R, Woodgett JR. Current Biology 1996; 6:1664-1668.
203. Yost C, Torres M, Miller JR, Huang E, Kimelman D, Moon RT. The axis-inducing activity, stability, and subcellular distribution of β-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Genes and Development 1996; 10:1443-1453.
204. Wagner U, Utton M, Gallo JM, Miller CCJ. Cellular phosphorylation of tau by GSK-3β influences tau binding to microtubules and microtubule organisation. Journal of Cell Science 1996; 109:1537-1543.
205. Ikeda S, Kishida S, Yamamoto H, Murai H, Koyama S, Kikuchi A. Axin, a negative regulator of the Wnt signalling pathway forms a complex with GSK-3β and β-catenin. Embology Journal 1997; 17:1371-1384.
206. Lucas FR, Salinas PC. WNT-7a induces axonal remodeling and increases synapsin I levels in cerebellar neurons. Developmental Biology 1997; 192:31-44.
207. Chen G, Huang LD, Jiang YM, Manji HK. The mood stabilising agent Valproate inhibits the activity of glycogen synthase kinase 3. Journal of Neurochemistry 1999; 72:1327-1330.
208. Chen G, Zeng WZ, Jiang L, Yuan PX, Zhao J, Manji HK. The mood stabilizing agents lithium and valproate robustly increase the expression of the neuroprotective protein bc1-2 in the CNS. Journal of Neurochemistry 1999b; 72:879-882.
209. Liang P, Pardee AB. Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science 1992; 257:967-971.
210. Liang P, Bauer D, Averboukh L et al. Analysis of altered gene expression by differential display. Methods in Enzymology 1995; 254:304-321.
211. Liu P, Tarle SA, Hajra A et al. Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia. Science 1993; 261:1041-1044.
212. Kanno T, Kanno Y, Chen LF, Ogawa E, Kim WY, Ito Y. Intrinsic transcriptional activation-inhibition domains of the polyomavirus enhancer binding protein 2/core binding factor alpha subunit revealed in the presence of the beta subunit. Molecular Cell Biology 1998; 18:2444-2454.
213. Klampfer L, Zhang J, Zelenetz AO, Uchida H, Nimer SD. The AML1/ETO fusion protein activates transcription of Bc1-2. Proceedings of the National Academy of Sciences of the United States of America 1996; 26:14059-14064.
214. Jacobson MD, Raff M. Programmed cell death and Bc1-2 protection in very low oxygern. Nature 1995; 374:814-816.
215. Merry DE, Korsmeyer SJ. Bc1-2 gene family in the nervous system. Annual Revues in Neuroscience 1997; 20:245-267.
216. Lawrence MS, Ho DY, Sun GH, Steinberg GK, Sapolsky RM. Overexpression of Bc1-2 with herpes simplex virus vectors protects CNS neurons against neurological insults in vitro and in vivo. Journal of Neuroscience 1996; 16:486-496.
217. Elkis H, Friedman WA, Meltzer HY. Meta-analyses of studies of ventricular enlargement and cortical sulcal prominence in mood disorders. Comparisons with controls or patients with schizophrenia. Archives of General Psychiatry 1995; 51:735-746.
218. Rajkowska G, Selemon LD, Goldman-Rakic PS. Marked glial neuropathology in prefrontal cortex distinguishes bipolar disorder from schizophrenia. Schizophrenia Research 1997; 24:41.
219. Rajkowska G, Wei J, Pittman SD et al. Histopathology of the orbitofrontal cortex in major depression. Biological Psychiatry 1998; 43:307.
220. Manji HK, Moore GJ, Chen G. Lithium at 50: have the neuroprotective effects of this unique cation been overlooked? Biological Psychiatry 1999; 46:929-940.
221. Bruno V, Sortino MA, Scapagnini U, Nicoletti F, Canonico P. Antidegenerative effects of Mg(2+) -valproate in cultured cerebellar neurons. Functional Neurology 1995; 10:121-130.
222. Nonaka S, Chuang DM. Neuroprotective effects of chronic lithium on focal cerebral ischemia in rats. Neuroreport 1998; 9:2081-2084.
223. Chen RW, Chuang DM. Long term lithium treatment suppresses p53 and Bax expression but increases bc1-2 expression. Journal of Biological Chemistry 1999; 274:6039-6042.
224. Smith MA, Makino S, Altemus M et al. Stress and antidepressants differentially regulate neurotrophin 3 mRNA expression in the locus coeruleus. Proceedings of the National Academy of Sciences of the United States of America 1995; 92:8788-8792.